📊 VYNE Key Takeaways
Is VYNE Therapeutics Inc. (VYNE) a Good Investment?
VYNE faces critical financial distress with a sub-one-year cash runway ($24M cash versus $33.1M annual burn rate) despite minimal revenue generation ($570K). While the company has zero debt and improving loss metrics YoY, the combination of unsustainable operating cash burn and negligible revenue indicates urgent capital needs or potential insolvency risk without significant business inflection.
Why Buy VYNE Therapeutics Inc. Stock? VYNE Key Strengths
- Zero long-term debt and minimal liabilities ($2.4M) provides flexibility
- Revenue growth of +13.8% YoY shows some commercialization traction
- Net loss improved +33.5% YoY indicating cost management efforts
- Strong liquidity position ($24M cash, 12.53x current ratio)
VYNE Stock Risks: VYNE Therapeutics Inc. Investment Risks
- Critical cash runway of approximately 9 months at current $33.1M annual burn rate
- Minimal revenue generation ($570K) despite pharmaceutical sector positioning suggests product/market fit challenges
- Massive operating cash burn (-$33.1M) exceeds revenue by 58x, indicating unsustainable business model
- Imminent capital raise required; significant equity dilution likely if needed before cash depletion
- No interest coverage and negative operating margins of -5219% indicate operational losses across all segments
Key Metrics to Watch
- Cash burn rate trajectory and quarterly runway remaining
- Revenue growth acceleration and path to breakeven operations
- Capital raise announcements and dilution impact
- Operating expense trends and cost structure optimization
- Product commercialization milestones and market adoption
VYNE Therapeutics Inc. (VYNE) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 12.53x current ratio provides a solid financial cushion.
VYNE Profit Margin, ROE & Profitability Analysis
VYNE vs Healthcare Sector: How VYNE Therapeutics Inc. Compares
How VYNE Therapeutics Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is VYNE Therapeutics Inc. Stock Overvalued? VYNE Valuation Analysis 2026
Based on fundamental analysis, VYNE Therapeutics Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
VYNE Therapeutics Inc. Balance Sheet: VYNE Debt, Cash & Liquidity
VYNE Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: VYNE Therapeutics Inc.'s revenue has declined by 97% over the 5-year period, indicating business contraction. The most recent EPS of $-0.93 indicates the company is currently unprofitable.
VYNE Revenue Growth, EPS Growth & YoY Performance
VYNE Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2025 | $69.0K | -$5.8M | $-0.13 |
| Q1 2025 | $98.0K | -$6.2M | $-0.15 |
| Q3 2024 | $114.0K | -$6.6M | $-0.29 |
| Q2 2024 | $135.0K | -$9.4M | $-0.22 |
| Q1 2024 | $98.0K | -$5.6M | $-0.15 |
| Q3 2023 | $114.0K | -$6.6M | $-2.01 |
| Q2 2023 | $126.0K | -$3.8M | $-1.21 |
| Q1 2023 | $99.0K | $4.7M | $1.51 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
VYNE Therapeutics Inc. Dividends, Buybacks & Capital Allocation
VYNE SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for VYNE Therapeutics Inc. (CIK: 0001566044)
📋 Recent SEC Filings
❓ Frequently Asked Questions about VYNE
What is the AI rating for VYNE?
VYNE Therapeutics Inc. (VYNE) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are VYNE's key strengths?
Claude: Zero long-term debt and minimal liabilities ($2.4M) provides flexibility. Revenue growth of +13.8% YoY shows some commercialization traction.
What are the risks of investing in VYNE?
Claude: Critical cash runway of approximately 9 months at current $33.1M annual burn rate. Minimal revenue generation ($570K) despite pharmaceutical sector positioning suggests product/market fit challenges.
What is VYNE's revenue and growth?
VYNE Therapeutics Inc. reported revenue of $570.0K.
Does VYNE pay dividends?
VYNE Therapeutics Inc. pays dividends, with $16.5M distributed to shareholders in the trailing twelve months.
Where can I find VYNE SEC filings?
Official SEC filings for VYNE Therapeutics Inc. (CIK: 0001566044) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is VYNE's EPS?
VYNE Therapeutics Inc. has a diluted EPS of $-0.62.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is VYNE a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, VYNE Therapeutics Inc. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is VYNE stock overvalued or undervalued?
Valuation metrics for VYNE: ROE of -95.4% (sector avg: 15%), net margin of -4,646.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy VYNE stock in 2026?
Our dual AI analysis gives VYNE Therapeutics Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is VYNE's free cash flow?
VYNE Therapeutics Inc.'s operating cash flow is $-33.1M, with capital expenditures of $0.0. FCF margin is -5,811.2%.
How does VYNE compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -4,646.1% (avg: 12%), ROE -95.4% (avg: 15%), current ratio 12.53 (avg: 2).